Publication:
A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance

Files

A Novel Gemcitabine-Resistant Gallbladder Cancer ModelProvides Insights into Molecular Changes Occurring duringAcquired Resistance.pdf (556.05 KB)

Date

2023

Type:

Article

Collections

Artículos Medicina y Ciencias de la Salud

Descargas totales

245

Vistas totales

16
Gestores bibliográficos

Authors

item.contributor.advisor

ORCID:

Journal Title

Journal ISSN

Volume Title

Publisher

item.page.isbn

item.page.issn

item.page.issne

item.page.doiurl

https://doi.org/10.3390/ijms24087238

URI

https://hdl.handle.net/11447/8717

item.page.extent

item.page.accessRights

Acceso Abierto

item.page.other

item.page.references

Abstract

Treatment options for advanced gallbladder cancer (GBC) are scarce and usually rely on cytotoxic chemotherapy, but the effectiveness of any regimen is limited and recurrence rates are high. Here, we i...

Description

item.page.coverage.spatial

item.page.sponsorship

Citation

Vergara-Gómez L, Bizama C, Zhong J, Buchegger K, Suárez F, Rosa L, Ili C, Weber H, Obreque J, Espinoza K, Repetto G, Roa JC, Leal P, García P. A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance. Int J Mol Sci. 2023 Apr 14;24(8):7238. doi: 10.3390/ijms24087238.

Keywords

SILAC-based phosphoproteomics , acquired drug resistance , cytidine deaminase , epithelial-to-mesenchymal transition , gallbladder cancer , gemcitabine , gene expression profiling

item.page.dc.rights

item.page.dc.rights.url

Estadísticas de uso
1 0,8 0,5 0,3 0
Septiembre 2025Octubre 2025Noviembre 2025Diciembre 2025Enero 2026Febrero 2026Marzo 2026

Implementado por OpenGeek Services